financetom
Business
financetom
/
Business
/
Allete Acquisition by Investor Group Faces Objection From Minnesota Administrative Law Judge
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Allete Acquisition by Investor Group Faces Objection From Minnesota Administrative Law Judge
Jul 16, 2025 10:06 AM

12:30 PM EDT, 07/16/2025 (MT Newswires) -- Allete's ( ALE ) proposed acquisition by a partnership led by the Canada Pension Plan Investment Board and Global Infrastructure Partners doesn't meet Minnesota's public interest standard, Administrative Law Judge Megan McKenzie said Tuesday, according to a court document.

McKenzie recommended that the Minnesota Public Utilities Commission reject the petitioners' request for approval and directed Allete's ( ALE ) utility subsidiary, Minnesota Power, to disclose all costs tied to negotiating and seeking approval for the transaction, including employee time.

"Absent any speculation, what is presently known through the documentary evidence shows this transaction carries real and significant costs and risks to Minnesota ratepayers and few, if any, benefits," the judge wrote.

"We strongly disagree with the conclusions in this nonbinding recommendation," Allete ( ALE ) said Tuesday in a statement. The judge's report "mischaracterizes the parties, their agreements and plans, and the benefits and risks of the acquisition," the company said.

The report overlooks a recent settlement with the Minnesota Department of Commerce, "which would deliver immediate and significant customer benefits," Allete ( ALE ) said.

"The Minnesota Public Utilities Commission will make a final determination on the acquisition in the coming months," Allete ( ALE ) said.

Allete ( ALE ) agreed to be acquired in May 2024 for $6.2 billion, including debt.

The Canada Pension Plan Investment Board and Global Infrastructure Partners didn't immediately reply to requests for comments from MT Newswires.

Price: 66.09, Change: -0.30, Percent Change: -0.45

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Two US senators urge Tinder parent to act against dating scams on its apps
Two US senators urge Tinder parent to act against dating scams on its apps
Sep 24, 2025
(Reuters) -Two U.S. senators sent a letter to Tinder parent Match on Wednesday, pushing for action against dating scams on the company's platforms and asking for information about its efforts to detect frauds and protect its users. In a letter to Match CEO Spencer Rascoff, Democratic Senator Maggie Hassan and Republican Senator Marsha Blackburn asked the company to provide documents...
Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell
Biogen Says Leqembi Approved in Australia as Treatment for Alzheimer's Disease; Shares Up Pre-Bell
Sep 24, 2025
08:11 AM EDT, 09/24/2025 (MT Newswires) -- Biogen (BIIB) and Eisai said Wednesday that Australia's Therapeutic Goods Administration approved Leqembi for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease. The approval follows a review process after the regulatory agency initially did not approve the drug in February, the company said. Leqembi targets toxic protofibrils and...
Freeport-McMoRan expects lower consolidated sales for copper, gold in third quarter
Freeport-McMoRan expects lower consolidated sales for copper, gold in third quarter
Sep 24, 2025
Sept 24 (Reuters) - Miner Freeport-McMoRan said on Wednesday that it was expecting consolidated sales to be about 4% lower for copper and nearly 6% lower for gold in the third quarter, compared with its prior forecast. (Reporting by Pooja Menon in Bengaluru; Editing by Anil D'Silva) ...
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Harmony Biosciences' genetic disorder drug fails to meet main goal in late-stage trial
Sep 24, 2025
Sept 24 (Reuters) - Harmony Biosciences ( HRMY ) said on Wednesday its experimental drug for a type of rare genetic disorder failed to meet the main goal in a late-stage trial. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved